Taysha Gene Therapies, Inc.
TSHA
$3.27
$0.113.48%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Net Income | 18.90% | 26.47% | 19.96% | 89.38% | 7.66% |
Total Depreciation and Amortization | -13.84% | -11.87% | -9.19% | -4.39% | 2.36% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | -61.76% | -65.20% | -64.48% | -128.09% | -2.95% |
Change in Net Operating Assets | 33.27% | -36.20% | 30.79% | -197.01% | -208.79% |
Cash from Operations | -8.97% | -14.89% | -11.24% | -87.33% | -42.07% |
Capital Expenditure | -15.36% | -461.47% | 90.33% | 93.62% | 95.62% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 102.35% | 100.52% | 100.32% | 100.20% | -228.28% |
Cash from Investing | 91.38% | 83.46% | 95.06% | 96.03% | 58.44% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | 5.55% | -45.29% | -45.34% | -57.77% | 401.11% |
Repurchase of Common Stock | 14.89% | 14.89% | 14.89% | -- | -522.06% |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | 75.05% | 58.94% | 81.77% | 44.37% | 43.89% |
Cash from Financing | 7.56% | -43.94% | -43.78% | -59.98% | 402.80% |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 9.71% | -112.21% | -108.75% | -105.10% | 703.25% |